胱抑素C在估算肾小球滤过率中的重要性:PARADIGM-HF试验
在PARADIGM-HF试验的1966例心衰患者中,比较CKD-EPI肌酐-胱抑素C方程与仅肌酐方程估算eGFR。两方程eGFR差值中位数为-0.7 mL/min/1.73 m²,分别有11%和18%患者被重新分类至更好或更差的eGFR类别。胱抑素C方程估算eGFR更低者死亡风险更高,且与生物标志物升高和健康状况恶化相关。
要点
- 胱抑素C方程估算eGFR更低者死亡风险更高,更高者死亡风险更低。
- 仅肌酐方程可能高估病情较重心衰患者的GFR。
核心结论
- 仅肌酐CKD-EPI方程可能高估病情较重心衰患者的GFR。
研究设计与样本
- PARADIGM-HF试验子分析,纳入1966例随机化时有胱抑素C和肌酐数据的患者。
主要发现
- 两方程eGFR差值中位数(四分位距)为-0.7(-6.4至4.8)mL/min/1.73 m²。
- 212例(11%)和355例(18%)患者分别被重新分类至更好和更差的eGFR类别。
- 与差值在-10至10 mL/min/1.73 m²之间的患者相比,胱抑素C方程eGFR低超过10 mL/min/1.73 m²者死亡率更高,高超过10 mL/min/1.73 m²者死亡率更低。
- eGFR差值增大(胱抑素C方程较肌酐方程eGFR更低)与NT-proBNP和肌钙蛋白等生物标志物升高及KCCQ临床总结评分恶化相关。
- 方程分歧随心衰严重程度增加的原因在于肌酐上升不如胱抑素C陡峭。
临床怎么用
- 在心衰患者中评估肾功能时,应考虑使用肌酐-胱抑素C联合方程以减少仅肌酐方程对GFR的高估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation combining creatinine and cystatin C provides a better estimation of glomerular filtration rate (GFR) compared to the creatinine-only equation. METHODS AND RESULTS: CKD-EPI creatinine-cystatin C equation (creatinine-cystatin) was compared to creatinine-only (creatinine) equation in a subpopulation of Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF). Patients were categorized according to difference in eGFR using the two equations: Group 1 (<-10 mL/min/1.73 m2, i.e. creatinine-cystatin more than 10 mL/min lower than creatinine), Group 2 (>-10 and <10 mL/min/1.73 m2), and Group 3 (>10 mL/min/1.73 m2, i.e. creatinine-cystatin more than 10 mL/min higher than creatinine). Cystatin C and creatinine were available in 1966 patients at randomization. Median (interquartile range) eGFR difference was -0.7 (-6.4-4.8) mL/min/1.73 m2. Compared to creatinine, creatinine-cystatin led to a substantial reclassification of chronic kidney disease stages. Overall, 212 (11%) and 355 (18%) patients were reallocated to a better and worse eGFR category, respectively. Compared to patients in Group 2, those in Group 1 (lower eGFR with creatinine-cystatin) had higher mortality and those in Group 3 (higher eGFR with creatinine-cystatin) had lower mortality. Increasing difference in eGFR (due to lower eGFR with creatinine-cystatin compared to creatinine) was associated with increasing elevation of biomarkers (including N-terminal pro-B-type natriuretic peptide and troponin) and worsening Kansas City Cardiomyopathy Questionnaire clinical summary score. The reason why the equations diverged with increasing severity of heart failure was that creatinine did not rise as steeply as cystatin C. CONCLUSION: The CKD-EPI creatinine-only equation may overestimate GFR in sicker patients. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT01035255.
引用
- Tolomeo P, Butt JH, Kondo T, et al. Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. Eur Heart J. 2023. PMID: 37051752. doi:10.1093/eurheartj/ehad210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。